Table 7.
Group (n = 25 per group) and average lipid panel comparisons between Visits 2 and 3.
| 100 mg of DYM | 100 mg of DYM + 50 mg of TCR | 150 mg of DYM + 25 mg of TCR | 150 mg of DYM | Placebo | Average | ||
|---|---|---|---|---|---|---|---|
| Total Cholesterol (mg/dL) |
Visit 2 | 158 ± 26 | 167 ± 30 | 155 ± 34 | 145 ± 22 | 175 ± 22 | 160 ± 28 |
| Visit 3 | 160 ± 35 | 166 ± 24 | 157 ± 34 | 148 ± 23 | 167 ± 34 | 160 ± 31 | |
| Triglycerides (mg/dL) |
Visit 2 | 69.8 ± 29.7 | 86.3 ± 39.6 | 84.9 ± 32.2 | 84.3 ± 39.5 | 96.0 ± 60.6 | 84.3 ± 41.8 |
| Visit 3 | 75.3 ± 31.9 | 77.8 ± 35.5 | 91.1 ± 41.3 | 83.4 ± 30.5 | 82.2 ± 44.1 | 81.9 ± 36.8 | |
| High-Density Lipoproteins (mg/dL) |
Visit 2 | 63.8 ± 13.9 | 56.7 ± 13.7 | 59.3 ± 12.4 | 54.7 ± 12.3 | 58.2 ± 17.4 | 58.5 ± 14.1 |
| Visit 3 | 63.2 ± 14.0 | 60.0 ± 16.1 | 61.1 ± 15.6 | 59.5 ± 14.2 | 57.4 ± 22.2 | 60.2 ± 16.5 * | |
| Very-Low-Density Lipoproteins (mg/dL) |
Visit 2 | 13.9 ± 6.0 | 17.2 ± 7.9 | 15.4 ± 5.5 | 15.8 ± 7.9 | 18.0 ± 11.6 | 16.0 ± 8.0 |
| Visit 3 | 15.0 ± 6.6 | 15.8 ± 7.4 | 16.8 ± 7.8 | 16.3 ± 6.1 | 17.2 ± 9.4 | 16.2 ± 7.4 | |
| Low-Density Lipoproteins (mg/dL) |
Visit 2 | 80.8 ± 21.0 | 93.8 ± 23.9 | 80.0 ± 28.5 | 74.9 ± 19.7 | 98.6 ± 22.4 | 85.6 ± 24.6 |
| Visit 3 | 81.6 ± 26.9 | 90.2 ± 24.2 | 79.5 ± 27.3 | 72.3 ± 20.1 | 96.4 ± 24.4 | 84.2 ± 25.7 |
* Significantly (p < 0.05) different from Visit 2.